The PE Ratio as of November 2024 (TTM) for Phathom Pharmaceuticals, Inc. (PHAT) is -1.63

According to Phathom Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.63. This represents a change of -24.66% compared to the average of -2.16 of the last 4 quarters.

Phathom Pharmaceuticals, Inc. (PHAT) Historical PE Ratio (quarterly & annually)

How has PHAT PE Ratio performed in the past?

The mean historical PE Ratio of Phathom Pharmaceuticals, Inc. over the last ten years is -30.83. The current -1.63 PE Ratio has changed 428.66% with respect to the historical average. Over the past ten years (40 quarters), PHAT's PE Ratio was at its highest in in the June 2019 quarter at -0.60. The PE Ratio was at its lowest in in the September 2018 quarter at -181.92.

Phathom Pharmaceuticals, Inc. (PHAT) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Phathom Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Phathom Pharmaceuticals, Inc. (PHAT) Average PE Ratio

How has PHAT PE Ratio performed in the past?

The current PE Ratio of Phathom Pharmaceuticals, Inc. (PHAT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Phathom Pharmaceuticals, Inc. (PHAT) PE Ratio vs. Peers

How is PHAT’s PE Ratio compared to its peers?

Phathom Pharmaceuticals, Inc.’s PE Ratio is greater than Day One Biopharmaceuticals, Inc. (-15.73), greater than Blueprint Medicines Corporation (-46.60), less than Lyra Therapeutics, Inc. (-0.13), greater than Cullinan Oncology, Inc. (-5.10), greater than Acumen Pharmaceuticals, Inc. (-1.74), greater than X4 Pharmaceuticals, Inc. (-4.05), greater than Inozyme Pharma, Inc. (-1.84), greater than VectivBio Holding AG (-7.94), greater than Kiniksa Pharmaceuticals, Ltd. (-168.32), greater than Structure Therapeutics Inc. (-14.91), greater than Karuna Therapeutics, Inc. (-37.08), greater than Immix Biopharma, Inc. (-2.41), less than CNS Pharmaceuticals, Inc. (-0.16), less than Hepion Pharmaceuticals, Inc. (-0.20), less than Freeline Therapeutics Holdings plc (-1.01), less than AVROBIO, Inc. (2.07), greater than Terns Pharmaceuticals, Inc. (-5.12), less than Amylyx Pharmaceuticals, Inc. (-1.38),

Build a custom stock screener for Phathom Pharmaceuticals, Inc. (PHAT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Phathom Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Phathom Pharmaceuticals, Inc. (PHAT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Phathom Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.